N-hexacosanol prevents diabetes-induced rat ileal dysfunction without qualitative alteration of the muscarinic

Naho Narimatsu1, Motoaki Saito, Emi Kazuyama

  • 1Department of Pathophysiological and Therapeutic Science, Division of Molecular Pharmacology, Tottori University Faculty of Medicine, Nishimachi, Yonago.

Insights

N-hexacosanol prevents carbachol-induced hypercontractility in diabetic rat ileum by targeting muscarinic M(3) receptors. This long-chain fatty alcohol also reduces diabetes-induced up-regulation of muscarinic M(2) and M(3) receptor mRNAs.

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Endocrinology

Background:

  • Diabetic gastrointestinal dysfunction is a common complication.
  • Muscarinic receptors play a role in regulating intestinal motility.
  • Alterations in muscarinic receptor expression are observed in diabetic states.

Purpose of the Study:

  • To investigate the effects of N-hexacosanol on muscarinic receptor function in diabetic rat ileum.
  • To determine if N-hexacosanol can ameliorate carbachol-induced hypercontractility in diabetic ileum.
  • To examine the impact of N-hexacosanol on muscarinic M(2) and M(3) receptor expression in diabetic rats.

Main Methods:

  • Diabetes was induced in Sprague-Dawley rats using streptozotocin.
  • Rats were treated with varying doses of N-hexacosanol.
  • Ileum function was assessed using organ bath studies with carbachol and KCl.
  • Muscarinic receptor expression (M(2) and M(3)) was quantified using real-time PCR.
  • Subtype-selective muscarinic antagonists were employed to characterize receptor involvement.

Main Results:

  • N-hexacosanol treatment did not affect the overall diabetic status of the rats.
  • N-hexacosanol significantly prevented carbachol-induced hypercontractility in the diabetic rat ileum.
  • Carbachol-induced contractile responses were primarily mediated by the muscarinic M(3) receptor subtype.
  • N-hexacosanol significantly attenuated the diabetes-induced upregulation of muscarinic M(2) and M(3) receptor mRNAs.

Conclusions:

  • N-hexacosanol demonstrates preventive effects against carbachol-induced hypercontractility in the diabetic rat ileum.
  • The protective action of N-hexacosanol is associated with the modulation of muscarinic M(3) receptor activity.
  • N-hexacosanol mitigates diabetes-induced changes in intestinal muscarinic M(2) and M(3) receptor mRNA expression.

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...